Paul Brooks has been promoted to the position of chief executive at CN Bio Innovations Ltd to oversee the next stage in the commercialisation of the company’s organ-on-a-chip technology. He was previously chief business officer. He succeeds David Hughes who will perform a consultative role within the company’s scientific advisory board.
Dr Brooks was previously head of business operations at Horizon Discovery Group Plc, a gene editing company. He has also been chief commercial officer at Oxford Genetics Ltd. He holds a PhD in molecular biology from the University of Manchester Institute of Science and Technology and an MBA from Nottingham University Business School, both in the UK.
CN Bio announced the appointment on 19 December 2022.
Copyright 2022 Evernow Publishing Ltd